Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert C Moellering

Showing results (11-20 of 62) with videos related to

Pageof 7
Sort By:
The Journal of Infection|September 22, 2009
New treatments for multiply drug-resistant Gram-positive bacteriaRobert C Moellering
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 18, 2013
Tedizolid: a novel oxazolidinone for Gram-positive infectionsRobert C Moellering
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 26, 2002
The continuing challenge of lower respiratory tract infectionsRobert C Moellering
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 3, 2005
Vancomycin: a 50-year reassessmentRobert C Moellering
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 2, 2009
What is inadequate antibacterial therapy?Robert C Moellering
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 28, 2008
Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strainsGeorge Sakoulas, Robert C Moellering
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 5, 2002
The United States Food and Drug Administration and the end of antibioticsDavid M Shlaes, Robert C Moellering
The Lancet. Infectious Diseases|January 29, 2008
Telithromycin and the FDA: implications for the futureDavid M Shlaes, Robert C Moellering
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 8, 2003
Microbial resistance: bacteria and moreMartin J Wood, Robert C Moellering
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 5, 2007
The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureusFred C Tenover, Robert C Moellering
Pageof 7

Showing results (11-20 of 62) with videos related to

Sort By:
Pageof 7
The Journal of Infection|September 22, 2009
New treatments for multiply drug-resistant Gram-positive bacteriaRobert C Moellering
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 18, 2013
Tedizolid: a novel oxazolidinone for Gram-positive infectionsRobert C Moellering
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 26, 2002
The continuing challenge of lower respiratory tract infectionsRobert C Moellering
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 3, 2005
Vancomycin: a 50-year reassessmentRobert C Moellering
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 2, 2009
What is inadequate antibacterial therapy?Robert C Moellering
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 28, 2008
Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strainsGeorge Sakoulas, Robert C Moellering
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 5, 2002
The United States Food and Drug Administration and the end of antibioticsDavid M Shlaes, Robert C Moellering
The Lancet. Infectious Diseases|January 29, 2008
Telithromycin and the FDA: implications for the futureDavid M Shlaes, Robert C Moellering
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 8, 2003
Microbial resistance: bacteria and moreMartin J Wood, Robert C Moellering
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 5, 2007
The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureusFred C Tenover, Robert C Moellering
Pageof 7